Suppliers and packagers for TORISEL

TORISEL

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Pf Prism Cv	TORISEL	temsirolimus	SOLUTION;INTRAVENOUS	022088	NDA	Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.	0008-1179-01	1 KIT in 1 CARTON (0008-1179-01) * 25 mL in 1 VIAL, SINGLE-USE (0008-1279-01) * 1.8 mL in 1 VIAL, SINGLE-USE (0008-1125-01)	2007-07-01

Suppliers for the Pharmaceutical Drug: TORISEL (Temsirolimus)

Last updated: July 31, 2025

Introduction

TORISEL (temsirolimus) is an mTOR (mechanistic target of rapamycin) inhibitor approved primarily for the treatment of advanced renal cell carcinoma (RCC). As a specialized oncology agent, TORISEL’s manufacturing and supply chain are critical for ensuring consistent access to this targeted therapy. This article provides a comprehensive analysis of the key suppliers involved in the production, formulation, and distribution of TORISEL, alongside insights into the regulatory landscape and strategic considerations for stakeholders.

Manufacturers of Active Pharmaceutical Ingredient (API)

1. Wyeth Pharmaceuticals

Historically, Wyeth (now a part of Pfizer following its 2009 acquisition) was the original manufacturer of temsirolimus API. Pfizer has since continued to supply and manufacture the API to meet global demand, leveraging its extensive biopharmaceutical manufacturing infrastructure. Although detailed publicly available manufacturing site information remains confidential, Pfizer’s global API production facilities in the United States and Europe are significant contributors to the supply chain.

2. Contract Manufacturing Organizations (CMOs)

Due to high development costs and regulatory complexities, pharmaceutical companies often outsource API production to CMOs specializing in complex small-molecule synthesis. Notable CMOs involved in temsirolimus API manufacturing include:

• Lonza: A Swiss-based contract manufacturer with a robust portfolio in complex molecule synthesis; known for high-quality GMP API production.
• Boehringer Ingelheim BioXcellence: Prior reported capacity in producing mTOR inhibitors and related compounds, with GMP certification for small-molecule APIs.
• Biocon: As a leading Indian biopharmaceutical company with established API manufacturing capabilities, albeit primarily focused on biologics, Biocon’s involvement in complex small-molecule APIs like temsirolimus is emerging as a strategic avenue.

Formulation and Finished Dosage Form Suppliers

3. Merck KGaA (Eli Lilly co-distributor)

Following licensing agreements, Merck KGaA (formerly EMD Serono in the US and Canada) has been a prominent distributor and marketer of TORISEL. The formulation, including injectable vials containing 25 mg of temsirolimus, is produced at Merck’s manufacturing facilities, ensuring quality control in sterile processing.

4. Contract Fill-Finish & Packaging

The final stages—including vial filling, labeling, and packaging—are outsourced to specialized sterile facility providers such as:

• Sterile Processing Companies: These include companies like Samsung BioLogics and Catalent, which possess large-scale sterile fill-finish capacities for oncology injectables.
• Regional Packaging Partners: Many regional pharmaceutical contract packagers are involved in the distribution network, depending on geographic market requirements.

Distribution and Supply Chain

The global distribution network involves several tiers:

• Authorized Distributors: Major pharmaceutical distributors such as McKesson, Cardinal Health, and AmerisourceBergen facilitate supply to hospitals and clinics.
• Regional and Local Distributors: These entities ensure timely delivery and inventory management, especially across Europe, North America, and Asia-Pacific.

Supply chain integrity depends heavily on cold chain logistics, quality assurance protocols, and regulatory compliance, especially given the drug’s injectable form and oncology indication.

Regulatory Landscape and Implications for Suppliers

Manufacturers must comply with stringent GMP (Good Manufacturing Practices) standards set by agencies such as the FDA (U.S. Food and Drug Administration), EMA (European Medicines Agency), and other national authorities. These standards govern API synthesis, formulation, and packaging processes, limiting the pool of qualified suppliers.

Supply chain disruption risks—such as manufacturing delays, geopolitical issues, or raw material shortages—can significantly impact availability. Recent trends indicate increased scrutiny on API sourcing, emphasizing transparency and supply chain resilience from pharmaceutical companies and regulatory entities alike.

Strategic Considerations for Stakeholders

• Vertical Integration: Major pharmaceutical firms may seek vertical integration to secure API supply and reduce dependency on external CMOs.
• Geographic Diversification: Companies diversify manufacturing sites to mitigate regional risks, especially amid geopolitical tensions.
• Supply Chain Transparency: Growing regulatory emphasis on supply chain traceability necessitates partnerships with validated suppliers.

Emerging Trends and Future Outlook

• Biotech Innovation: The advent of biopharmaceutical approaches in oncology could diversify supply options in the long term; however, small-molecule APIs like temsirolimus remain reliant on traditional chemical synthesis.
• API Market Competition: As patents for TORISEL have expired or are nearing expiry, generic manufacturing capacity increases, potentially lowering costs and expanding supply options.
• Global Capacity Expansion: Asia-Pacific, particularly India and China, is accelerating API manufacturing capabilities for oncology drugs, which could influence future supplier dynamics.

Conclusion

The supply landscape for TORISEL encompasses a combination of original manufacturers, CMOs, and distribution partners. Pfizer and Merck KGaA are key players in manufacturing and distributing the drug, supported by strategic CMO partnerships worldwide. Reliable supply depends on adherence to regulatory standards, manufacturing robustness, and resilient logistics. Stakeholders must monitor evolving manufacturing capacities, geopolitical influences, and regulatory frameworks to ensure uninterrupted access to this critical oncology therapy.

Key Takeaways

• Market players rely heavily on Pfizer and Merck KGaA for core API production, with CMOs playing a vital complementary role.
• Supply chain resilience is paramount due to high regulatory standards and complex manufacturing processes.
• Emerging manufacturing capacities in Asia-Pacific will shape future API availability and cost dynamics.
• Patent expirations and generic entry may increase supply options but require quality assurance.
• Regulatory rigor influences supplier qualification, reducing vulnerability to supply disruptions.

FAQs

1. Who are the primary suppliers of temsirolimus API for TORISEL?
   Pfizer remains the principal API supplier, with several CMOs, including Lonza and Boehringer Ingelheim, involved in manufacturing complex small-molecule APIs.

2. Are there alternative sources of temsirolimus in the market?
   Patents for TORISEL have expired or are expiring, enabling generic manufacturers—primarily based in India and China—to produce temsirolimus, increasing supply diversity.

3. How does supply chain complexity affect TORISEL availability?
   The drug’s complex synthesis, regulatory requirements, and specialized sterile formulation create potential risks for shortages, necessitating diversified manufacturing and distribution strategies.

4. What role do contract manufacturing organizations play in the supply of TORISEL?
   CMOs handle large-scale API production, ensuring capacity beyond the original manufacturer, and support formulation, fill-finish, and packaging processes.

5. Will future innovations impact the supply of TORISEL?
   While future biologics and targeted therapies could influence demand, current supply chains for small-molecule mTOR inhibitors like temsirolimus are expected to remain stable given existing manufacturing infrastructure and patent status.

Sources:

[1] Pfizer Official Website. Temsirolimus (TORISEL) Product Information.
[2] European Medicines Agency. TORISEL (temsirolimus) Summary of Product Characteristics.
[3] Industry reports on API manufacturing capacities, 2022–2023.
[4] Regulatory filings and patent documents related to temsirolimus.

---

Note: The specifics regarding manufacturing sites and contractual agreements are often confidential; this overview synthesizes publicly available information and industry insights.